Novo Nordisk ramping up insulin production with 450-job project

If you listen to drugmakers talk, the world diabetes market is fraught with peril. Novo Nordisk CEO Lars Rebien Sørensen speaks of stingy payers and global competition, while Sanofi ($SNY) says its diabetes drug sales will fall through 2018. But none of this has deterred insulin specialist Novo, which kicked off one piece of a huge production buildup on Wednesday. All told, the expansion will add more than 1,200 jobs to the drugmaker. More from FiercePharma

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.